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ABSTRACT 57 
Pneumococcal pneumonia causes an estimated 105,000 child deaths in India annually. The 58 
planned introduction of the serotype-based pneumococcal conjugate vaccine (PCV) is 59 
expected to avert child deaths, but the high cost of PCV relative to current vaccines provided 60 
under the Universal Immunization Programme has been a concern. Cost-effectiveness studies 61 
from high-income countries are not readily comparable because of differences in the 62 
distribution of prevalent serotypes, population, and health systems. We used IndiaSim, an 63 
agent-based simulation model representative of the Indian population and health system, to 64 
model the dynamics of Streptococcus pneumoniae. We estimate that PCV13 introduction 65 
would cost approximately $240 million and avert $48.7 million in out-of-pocket expenditures 66 
and 34,800 (95% confidence interval [CI] 29,600±40,800) deaths annually assuming 67 
coverage levels and distribution similar to DPT (diphtheria, pertussis, and tetanus) 68 
vaccination (~77%). Introducing the vaccine protects the population, especially the poorest 69 
wealth quintile, from potentially catastrophic expenditure. The net-present value of predicted 70 
money-metric value of insurance for 20 years of vaccination is $160,000 (95% CI $151,000ʹ71 
$168,000) per 100,000 under-fives, and almost half of this protection is for the bottom wealth 72 
quintile ($78,000; 95% CI 70,800Ͷ84,400). Extending vaccination to 90% coverage averts 73 
additional lives and provides additional financial risk protection. Our estimates are sensitive 74 
to immunity parameters in our model; however, our assumptions are conservative, and if 75 
willingness to pay per years of life lost (YLL) averted is $228 or greater then introducing the 76 
vaccine is more cost-effective than our baseline (no vaccination) in more than 95% of 77 
simulations.   78 
 79 
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SUMMARY BOX 84 
What is already known about the topic? 85 
x Streptococcus pneumoniae was responsible for an estimated 105,000 pneumonia 86 
deaths in India in 2010, in addition to causing meningitis and other forms of invasive 87 
disease. 88 
x The pneumococcal conjugate vaccine (PCV) greatly reduced disease burden in high-89 
income countries (HICs); however, the effectiveness and impact of PCV (including 90 
serotype replacement) varied significantly between countries, and it is significantly 91 
PRUHH[SHQVLYHWKDQRWKHUYDFFLQHVLQ,QGLD¶V8QLYHUVDO,PPXQL]DWLRQ3URJUDmme 92 
(UIP).  93 
x 7RFLUFXPYHQWWKHSDXFLW\RILQIRUPDWLRQRQWKHYDFFLQH¶VHIIHFWLYHQHVVLQORZ- and 94 
middle-income countries (LMICs), economic analyses of PCV in LMICs typically 95 
assume similar effectiveness as in HICs. 96 
What are the new findings 97 
x The local distribution of dominant serotypes, host population characteristics and 98 
EHKDYLRXUDQGYDFFLQDWLRQSURJUDPVDIIHFWWKHYDFFLQH¶VHIIHFWLYHQHVV 99 
x Despite uncertainty, we project that the vaccine will avert a significant number of 100 
deaths, provide financial risk protection for poor populations, and deliver value for the 101 
cost as assessed by the World Health Organization¶V cost-effectiveness guidelines. 102 
Recommendations for policy 103 
x Economic analysis should consider local context and the dynamics of S. pneumoniae 104 
transmission and serotype replacement within that setting. 105 
x Given our conservative assumptions and our projections of PCV13 effectiveness and 106 
impact in India, we recommend including PCV13 in the UIP, though we caution that 107 
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existing data gaps remain and the vaccine¶V effectiveness should be continuously 108 
monitored as it is rolled out.  109 
110 
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INTRODUCTION 111 
Streptococcus pneumoniae was responsible for an estimated 393,000 (95% uncertainty 112 
interval [UI] 228,000±532,000) child pneumonia deaths globally in 2015, with nearly all 113 
mortality occurring in low- and middle-income countries (LMICs) [1]. The introduction of a 114 
seven-valent pneumococcal conjugate vaccine (PCV7) in the early 2000s greatly reduced 115 
disease incidence and hospitalization in high-income countries (HICs), by reducing invasive 116 
pneumococcal disease (IPD), which occurs when S. pneumoniae invades normally sterile 117 
sites such as the bloodstream  [2]. PCV7 provided protection against the seven most common 118 
serotypes causing IPD in the United States at the time, and countries have since adopted 119 
expanded PCVs that provide protection against serotypes estimated to cause approximately 120 
70% of IPD globally [3]. Today, 135 countries include a PCV in their national immunization 121 
program [4]. 122 
 123 
In India, an estimated 105,100 (95% confidence interval [CI] 92,100±120,000) of 356,300 124 
(CI 311,600±407,400) under-five pneumonia deaths were associated with S. pneumoniae in in 125 
2010 [5]. In 2016, the National Technical Advisory Group on Immunization (NTAGI) 126 
recommended introducing a PCV in the universal immunization programme (UIP), which 127 
targets a cohort of 27 million newborns with six vaccines across the country and another two 128 
vaccines (against rotavirus and Japanese encephalitis) in a few states. The Indian government 129 
had planned to roll out PCV in three states in 2017, but progress remains slow in part due to 130 
the relatively high cost of PCV compared to other vaccines already provided under UIP [6±131 
8]. The Global Alliance for Vaccines and Immunization (GAVI) has pledged to support PCV 132 
provision until 2021 [9], after which the cost of the vaccine will have to be borne by the 133 
Indian government. The affordability and cost-effectiveness of the vaccine is especially 134 
important in resource-constrained countries, such as India. Prior analyses in several HICs 135 
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have found PCV introduction to be cost-saving or cost-effective according to World Health 136 
Organization (WHO) or local thresholds [10±13], but retrospective studies in other HICs, 137 
such as the Netherlands and Australia, found it unlikely that the PCV7 vaccination 138 
programme was cost-effective [14,15]. 139 
 140 
,QDGGLWLRQWR3&9¶VUHODWLYHO\KLJKFRVWWhe uncertainty regarding the vaccine¶s potential 141 
cost-effectiveness in LMICs stems from uncertainty surrounding its effectiveness in these 142 
settings [6,7,14]. The incidence of vaccine serotype (VT) IPD fell markedly in many HICs 143 
after the vaccine was introduced, but decreases in overall IPD varied significantly (e.g., IPD 144 
decreased by 12% in Navarro, Spain while in the United States it decreased by 77%, see 145 
[16]). The increase in the frequency of S. pneumoniae serotypes not covered by the vaccine, 146 
also known as serotype replacement, contributed to this variation in overall IPD. In LMICs, 147 
evidence on the effect of serotype replacement on overall vaccine effectiveness in the 148 
population is lacking. Evidence on PCV from randomized control trials (RCTs) in LMICs 149 
demonstrated that PCV7 and PCV9 are highly efficacious at reducing pneumonia and 150 
invasive disease [17±19]. But RCTs are not designed to evaluate serotype replacement at the 151 
population level. 152 
  153 
Recent observational studies of the introduction of a PCV in South Africa (PCV7 in 2009) 154 
and the Gambia (PCV13 in 2011) found that IPD in children under two dropped by 69% (CI 155 
62±76) and 55% (CI 30±71) within one year of introduction, respectively. However, both 156 
studies found that disease caused by non-vaccine serotypes (NVTs) was increasing, and, in 157 
the case of Gambia, overall IPD increased in the final year of the study [20±22]. In South-158 
East Asia, both Bangladesh and Nepal introduced PCVs in 2015, but data on effectiveness 159 
and serotype replacement have not been published [4]. 160 
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 161 
Economic analyses of introducing PCV need to consider the dynamics of S. pneumoniae 162 
transmission within the context of the setting being analyzed. Local differences in 163 
distributions of dominant serotypes, host populations, health system structure, and 164 
YDFFLQDWLRQSURJUDPVDOOFRQWULEXWHWRWKHYDULDWLRQLQWKHYDFFLQH¶VLPSDFWDFURVVFRXQWULHV165 
[23]. To estimate PCV outcomes given these factors, models need to consider the colonizedͶ166 
asymptomatic carrierͶpopulation, which is the reservoir of transmission. In HICs that 167 
introduced PCV, serotype replacement among colonized individuals was higher and more 168 
consistent than serotype replacement in IPD. A logical explanation for higher replacement 169 
among the colonized individuals than in IPD cases is that NVTs cause less disease than VTs. 170 
If this is the case, the variation in reduced IPD across countries may be partially attributable 171 
to local differences in the distribution of colonizing serotypes. Other theories have been 172 
proposed to explain the higher serotype replacement seen in colonization than in IPD [16], 173 
and projecting the dynamics of S. pneumoniae transmission in LMICs with a paucity of data 174 
is difficult. Nonetheless, evaluations of PCV introduction need to consider these economic-175 
epidemiological dynamics. They need to project serotype dynamics within the local context, 176 
or, at the very least, they should consider that the outcomes may not be the same in high-177 
burden-LMICs instead of current practice that either ignores the disease dynamics all together 178 
or assumes similar herd effects and serotype replacement as in low-burden-high-income 179 
settings (see [24±28]).   180 
 181 
To project trends in under-five pneumococcal infections, including bacteremic and non-182 
bacteremic pneumonia, meningitis, and other IPD, and estimate the potential financial risk 183 
protection, cost, and cost-effectiveness of introducing PCV in the UIP, we modelled S. 184 
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pneumoniae dynamics in an agent-based model (ABM) of the Indian population and 185 
healthcare system.  186 
 187 
METHODS 188 
Agent-based simulation model 189 
We adapted our survey-data driven ABM of an in silico population representative of the 190 
Indian population, IndiaSim [29±32]. Our simulated population size was approximately 191 
25,000 individuals and 4,300 households. Individuals in the simulation interacted with each 192 
other (contacts) and with the healthcare system, getting vaccinated and seeking care. 193 
Individuals were either healthy and not colonized, healthy and colonized, or colonized and 194 
symptomatically infected. Those symptomatically infected with S. pneumoniae chose 195 
whether to seek care. Individuals could also seek care for exogenous infections. Simulations 196 
were run with one-week time steps. Demographic and socioeconomic data and healthcare 197 
choices at the individual and household levels were drawn from the District Level Household 198 
Survey (DLHS-3) of India [33] and from literature on care seeking behaviour in India 199 
[34,35]. Additional details on IndiaSim are in the supplementary appendix and in previous 200 
publications [30±32]. The model was programmed in C++11 standard and outcomes analysed 201 
in R, version 3.2 [36].  202 
 203 
Pneumococcal colonization and transmission dynamics 204 
Pneumococcal disease dynamics were included in IndiaSim based on work by Cobey and 205 
Lipsitch [37]. We included 15 serotypes that are representative of the serotype distribution in 206 
India [38]; we did not model particular serotypes, but a representation of the S. pneumoniae 207 
population. 208 
 209 
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Transmission between individuals could occur when a carrier (or symptomatically infected) 210 
individual came into contact with other individuals. The probability of transmission of 211 
serotype ݖ depended on the susceptibility of the individual, a function of both current and 212 
historical colonizations and infections:  213 
 214 
 ݍ൫ݖǡ ߠԦǡ ܥԦ൯ ൌ ൣ⁡? െ ߱൫ܥԦ൯൧ ቂ⁡? െ ݉݅݊ ቀሺ⁡? െ ݌ሻǡ൫⁡?ǡ ߪ ⁡? ߬ሺݖሻ൯ቁቃ, (1)  
 215 
where ߠԦ and  ܥԦ are indicator vectors of past and current colonization, indexed by ݖ. Current 216 
colonization was assumed to reduce susceptibility through competition, described by the term 217 
in the first bracket in (1), where ߱൫ܥԦ൯ was set to: 218 
 219 
 ߱൫ܥԦ൯ ൌ ۖەۖ۔
ۓ ⁡?ǡ ෍ܥ௜ ൌ ⁡?ሺሻߤ௠௔௫ ൥⁡? െ݉ ݅݊൫ Ԧ݂൯ െ ⁡?ܼ െ ⁡? ൩ ǡ  ෍ܥ௜ ൐ ⁡?ሺሻǡ  (2)  
 220 
where ܼ is the number of serotypes in the model,  ߤ௠௔௫ is the maximum scaling down of 221 
susceptibility due to strain competition, and Ԧ݂ is a vector of serotype fitness ranks such that 222 ݉݅݊൫ Ԧ݂൯ is the rank of the most fit carried serotype. Serotype-specific immunity, described in 223 
the term in the second bracket in (1), also reduced susceptibility: ݌ is vaccine efficacy for the 224 
targeted serotypes, ߪ is an anticapsular immunity parameter (equivalent for all serotypes), 225 
and   226 
 227 
 ߬ሺݖሻ ൌ ൜⁡?ǡ ߠ௭ ൌ ⁡?ሺሻ⁡?ǡ ߠ௭ ൐ ⁡?ሺሻǤ  
 
(3)  
 228 
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The duration of colonization in successful transmissions was drawn from an exponential 229 
distribution in which the mean was:  230 
 231 
 ݒሺݖሻ ൌ ݇ ൅ ሾߛሺݖሻ െ ݇ሿ݁ିఢ ⁡? ఏ೔೔  (4)  
 232 
Serotypes were assumed to differ in their fitness, modelled as a reduction in the length of 233 
colonization (ߛሺݖሻ) [39,40]. Duration exponentially decreased with the sum of past 234 
colonizations (⁡? ߠ௜௜ ), describing the serotype-independent immunity. ݇ is the minimum 235 
duration of colonization and ߳ is a fitted shape parameter. Parameterization of colonization 236 
and transmission dynamics are based on Cobey and Lipsitch [37], which fits the functions to 237 
data from vaccine naïve populations. 238 
 239 
If the person sought care (either for S. pneumoniae infection or for an exogenous infection) 240 
and was prescribed antibiotics, duration was updated accordingly. Additional details of the 241 
dynamics are in the supplementary appendix and the model parameters are presented in Table 242 
1 and in the following text.  243 
 244 
Table 1. Parameters 245 
Description  Symbol§
  
Base-case  
[sensitivity values/distribution]  Source  
Disease model  
Number of serotypes  Z  15   
Under-five 
colonization 
prevalence fitted to  
 40%  Authors assumption based on [41±50].  
Contact rate  ȕ  Fitted to under-five 
colonization prevalence 
 
Immigration force of 
infection  Ȧ  1e-06 As in [37]  
Intrinsic duration of 
carriage for serotype 
z  
Ȗ]  25-220 days (linearly increasing 
across serotypes) 
As in [37], 
and based on [51,52]  
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Description  Symbol§
  
Base-case  
[sensitivity values/distribution]  Source  
Reduction in 
susceptibility to 
pneumococcus from 
carrying the fittest 
serotype  
ȝmax  0.25  As in [37]  
Reduction in 
susceptibility to a 
serotype conferred 
by prior carriage of 
that serotype  
ı  0.5 [0.5, 0.8]  0.5 based on results for Z = 15 in [37]  
Shape parameter for 
the reduction in 
duration of carriage 
dependent on past 
colonization  
İ  0.1 [0.1, 0.25, and 0.4]  Based on [37]  
Case-carrier ratio 
(pneumococcal 
pneumonia, 
meningitis, and 
other invasive 
pneumococcal 
disease)  
 
Fitted to disease incidence given 
colonization prevalence  Based on [53±55,5]  
Case fatality rate   Fitted to death rate  Based on [53,54,56,5] 
Treatment  
Seek treatment   Wealth quintile I: 48%; II: 51%; III: 60%; IV: 66%; V: 75%  Based on [34,57,35] 
Probability seek care 
at public provider (if 
seek care) 
 
- Wealth quintile I: 55% 
[triangular min = 44%, max = 
66%, mode = 55%]; 
 - II: 51% [triangular 40%, 61%, 
51%] 
- III: 43% [triangular 35%, 52%, 
43%);  
- IV: 39% [triangular 31%, 47%, 
39%];  
- V: 26% [triangular 21%, 32%, 
26%] 
 
Receive appropriate 
treatment at health 
provider  
 
95%  $XWKRUV¶DVVXPSWLRQ  
Inpatient meningitis 
cost  
  Based on [57±59]  
Public providers  $191 [triangular min = $134, 
max = $248, mode = $191] 
 
Private providers 
 
$275 [triangular min = $193, 
max = $358, mode = $275]  
In-patient pneumonia 
cost    Based on [57,59,60]  
Public providers  $93 [triangular min = $65, max 
= $121, mode = $93] 
 
Private providers 
 
$214 [triangular min = $150, 
max = $278, mode = $214]  
In-patient other 
pneumococcal 
disease cost  
  
Based on [57,59]  
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Description  Symbol§
  
Base-case  
[sensitivity values/distribution]  Source  
Public providers  $76 [triangular min = $53, max 
= $99, mode = $76] 
 
Private providers 
 
$194 [triangular min = $136, 
max = $252, mode = $194]  
Outpatient cost  
 
 Based on [57,59]  
Public providers  $7.55 [triangular min = $5.30, 
max = $9.80, mode = $7.55] 
 
Private providers 
 
$9.47 [triangular min = $6.60, 
max = $9.80, mode = $12.30]  
Unattended 
pneumonia cost  
$1.05 [triangular min = $0, max 
= $1.40, mode = $1.05] [61] 
Antibiotics clear 
colonization or 
symptomatic 
infection  
 
50%  Authors assumption based on Van Effelterre et al. 2010 [62±64] 
Exogenous antibiotic 
prescription rate (per 
day)  
 0.001327  Based on IMS Health MIDAS database  
Vaccine  
PCV13 % of cases  Most common serotypes 
representing approximately 70% Based on [38,65]. 
Per-person vaccine 
efficacy  p 0.6  
As in [37], 
estimated using [66]  
Per-child cost in 
scenario 1  
$13.60 [triangular min = $6.35, 
max = $18.95, mode = $13.60] Based on WHO cMYP tool.  
Per-child cost in 
scenario 2   
$13.50 [triangular min = $6.25, 
max = $18.85, mode = $13.50] Based on WHO cMYP tool.  
§Symbols for Cobey and Lipsitch 2012 model. 
Three doses at $3.30 per dose and training, syringe, wastage costs (5% vaccine wastage rate and 10% syringe 
wastage rate), and a 25% buffer stock. Ranges for the sensitivity assume $1 to $5 per dose. 
Values varied for sensitivity are in brackets. 
Costs in 2014 US dollars. 
 246 
Fitted pneumococcal colonization prevalence 247 
Studies from the past fifteen years found S. pneumoniae colonization prevalence in India 248 
ranging from 6.5% to 70.0% in children and infants [41±43,46±50,67,68]. We fit the contact 249 
rate (ȕ) so that the colonization levels of children under-five were ~40%.  250 
 251 
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Pneumococcal disease 252 
Carriers of S. pneumoniae became symptomatically infected²developed bacteremic or non-253 
bacteremic pneumococcal pneumonia, pneumococcal meningitis, or other invasive 254 
pneumococcal disease²according to the invasiveness, or case-carrier ratio. The case-carrier 255 
ratio represents infections per acquisition event, which we model as a function of the 256 
probability of progressing to symptomatic disease in a time-step and the duration of carriage 257 
(the number of time-steps). We assumed that VTs were carried for longer than NVTs [40], 258 
and therefore VTs case-carrier ratio was greater. We fit the case-carrier and case-fatality rates 259 
to estimates of disease incidence and deaths in the literature [56,54]. For more detail see 260 
supplementary appendix. 261 
 262 
Treatment and antimicrobial prescription 263 
Individuals suffering from pneumococcal disease sought care (i.e., went to hospital/clinic and 264 
received antibiotics) depending on their household wealth²wealthier individuals were more 265 
likely to seek care [34,35]. Similar to Kouyos and others [69], we assumed that rates of 266 
colonization were affected by individuals consuming antibiotics exogenously (i.e., for other 267 
causes). Antibiotic consumption rates were drawn from IMS Health MIDAS (IMS Health, 268 
Danbury, CT, USA) data on antibiotic consumption in India. The treatment costs for 269 
pneumococcal disease were based on Tasslimi and other [59] and include care seeking, 270 
diagnostics, hospitalization, and medication. 271 
 272 
Vaccination scenarios 273 
We evaluated three scenarios: (i) no vaccination; (ii) introducing PCV13 at DPT3 (diphtheria, 274 
pertussis, tetanus vaccine) coverage levels (approximately 77%) and following the 2+1 275 
schedule that India has adopted; and (iii) increasing PCV13 coverage to 90%. We assumed 276 
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that households that vaccinate with DPT in DLHS-3 continue to do so. We also increase 277 
coverage to 2011 estimates [70]; see previous work on rotavirus vaccination [30]. For the 278 
extended vaccination scenario, additional households were recruited randomly to increase 279 
vaccination coverage rates to 90%. 280 
 281 
The simulated vaccine did not protect against thirteen simulated serotypes. Instead, we 282 
assumed the vaccine provided protection against the most common serotypes that contributed 283 
70%±75% of disease incidence prior to vaccination [38,65]; this corresponded to 5 to 10 284 
simulated VTs, depending on the simulation parameterization. The vaccine was assumed to 285 
reduce susceptibility to asymptomatic carriage for VTs [37] as described by equation (1). The 286 
vaccine likely further protects against carriers progressing to disease, but due to lack of 287 
evidence, we conservatively assumed that the vaccine only affects susceptibility to 288 
colonization for covered serotypes and has no further effect on progression to disease (case-289 
carrier ratio).  290 
 291 
Data on immunization costs weUHIURP,QGLD¶V comprehensive multi-year plan (cMYP) for 292 
immunization [71]. It included costs for the vaccine and syringes²including wastage²and 293 
other related costs such as planning, training, transportation, and cold chain equipment.  294 
 295 
Analysis and outcome measures 296 
The primary outcome tracked was the change in under-five disease burden measured by 297 
estimated disease incidence and deaths averted. We report values for non-severe and severe 298 
pneumonia, pneumococcal meningitis, and other IPD. We consider both bacteremic and non-299 
bacteremic pneumonia, and the classification of severe pneumonia is based on the WHO 300 
definition used in Rudan et al [72] of lower chest wall indrawing, which represents an 301 
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indication for hospitalization. To measure serotype diversity, we calculated the Simpson 302 
index²the probability that two randomly selected serotypes (with replacement) will differ²303 
and compared it to limited data from India. We also estimated the years of life lost (YLLs) 304 
averted, the incremental cost-effectiveness (ICER) measured by the incremental cost per YLL 305 
averted from a health systems perspective (costs described above), out-of-pocket (OOP) 306 
expenditures averted, and the money-metric value of insurance (VOI)²the dollar amount the 307 
population would be willing to pay to avert the risk of financial shock from OOP expenditure 308 
on treatment [73].  309 
 310 
We ran simulations with fitted values for the contact rate, case-carrier ratio, and case-fatality 311 
rate for a 200-year burn-in period, before introducing vaccination and then estimating 312 
outcomes for the next twenty years. We report the rounded median present value for the 313 
twenty-year intervention timeframe and annual outcomes. For averted burden estimates, we 314 
report differences between median values for each scenario; for example, to estimate the 315 
deaths averted by the intervention in scenario 1 we subtract the median deaths in intervention 316 
scenario 1 from the median deaths in the no vaccination scenario. Costs and expenditures 317 
were converted to 2014 US dollars (see supplementary appendix), and we used a discount 318 
rate of 3%, consistent with standard practice.  319 
 320 
Sensitivity Analysis 321 
In addition to the base-case analysis, to assess the sensitivity of our results, we varied the 322 
parameters for anticapsular immunity and serotype-independent immunity as described in 323 
Table 1 since the interplay between naturally acquired and vaccine acquired immunity likely 324 
impacts strain dynamics and serotype replacement. We ran simulations with each parameter 325 
set (and fitted contact-rate, case-carrier ratio, and case-fatality rate as described above), in 326 
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total running 1,800 simulations, 600 for each scenario. We constructed 95% CIs by drawing 327 
5,000 bootstrap samples (e.g., of size 100 for base-case scenario 1 outcomes) from these 328 
simulations for each statistic we estimated. In addition, we explored the sensitivity of the 329 
ICERs to the immunity and economic parameters (Table 1); we set immunity parameters as 330 
described above and drew 5,000 samples from the joint distribution of the economic 331 
parameters. We constructed cost-effectiveness acceptability curves (CEAC) by calculating 332 
the proportion of bootstrap samples that had the highest net benefit for each arm, where the 333 
net benefit  ൌ ߣ ൈ ⁡?ܻܮܮ െ ⁡?ܿ݋ݏݐݏ and ߣ is the willingness to pay per YLL. 334 
 335 
RESULTS 336 
Serotype diversity 337 
To compare the serotype diversity in our model to results in Cobey and Lipsitch [37] and to 338 
data from India, we measured the Simpson index for our model outcomes and compared it to 339 
the 0.93 index calculated from data collected by Manoharan et al [65], which identified 57 340 
different serotypes and five non-typeable isolates. In our no vaccination simulations, the 341 
median Simpson index was 0.92 (95% CI 0.90±0.93). 342 
 343 
Disease burden 344 
We estimated that introducing PCV13 at current DPT coverage levels would avert a median 345 
481 (95% CI 456±502) non-severe pneumonia cases, 198 (95% CI 185±211) severe 346 
pneumonia cases, 3 (95% CI 3±4) meningitis cases, and 16 (95% CI 14±17) other invasive 347 
pneumococcal infections per 100,000 children under-five per year in the base-case (Figure 1). 348 
This represented a decline of 20.9% (95% CI 19.8%±22.1%) in severe pneumococcal 349 
pneumonia cases per year. The number of cases only stabilizes after five years, when it was 350 
25.2% (95% CI 24.2%±26.3%) and 34.2% (95% CI 31.9%±36.7%) lower per year in the DPT 351 
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and extended coverage scenarios than in the baseline scenario. Cases of non-severe 352 
pneumonia, meningitis, and other invasive pneumococcal disease were similarly reduced.  353 
 354 
Our results varied significantly depending on the sensitivity to immunity parameters, which 355 
affected the decline in under-five cases caused by VTs and serotype replacement by NVTs 356 
(Figure 2A). In DPT vaccination coverage simulations where we set the serotype-specific 357 
immunity parameter, which impacts susceptibility, to the base-case value ı= 0.5 (see 358 
equation 1) and increased the impact of serotype-independent immunity on colonization 359 
duration from the base-case by setting ׫ = 0.25 or ׫ = 0.4 (see equation 4), the number of 360 
cases dropped by 22.6% (95% CI 21.1%±23.9%) and 19.1% (95% CI 17.8%±20.5%) 361 
respectively. In simulations where we set the impact of serotype-specific immunity and 362 
serotype-independent immunity to the highest in our range (ı= 0.8 and ׫ = 0.4), the number 363 
of cases dropped by 9.8% (95% CI 8.5%±10.9%).  364 
 365 
VT symptomatic infections decreased and NVT symptomatic infections increased after the 366 
introduction of PCV13 for most parameter sets; there was no replacement by NVTs when 367 
immunity parameters were high (ı= 0.8 and ׫ = 0.4) (Figure 2B and C). The highest increase 368 
in NVTs was in simulations with low immunity parameter values; by the end of expanded 369 
coverage simulations, NVT cases increased by 50.8% (95% CI 45.0%ʹ57.0%) and VT cases 370 
decreased by 73.1% (95% CI 71.8%ʹ74.2%) among under-fives when immunity parameters 371 
were low (ı= 0.5 and ׫ = 0.1). The decline in VT cases was lower when we increased the 372 
anticapsular immunity parameter, ı, than when we increased the serotype-independent 373 
immunity parameter, ׫, and held other parameters at the base-case. For example, when ı= 374 
0.5 and ׫ = 0.4, VT cases decreased by 47.9% (95% CI 46.5%ʹ50.3%), and when ı= 0.8 and 375 
׫ = 0.1 VT cases decreased by 39.0% (95% CI 36.9%ʹ42.0%) by the end of simulation. 376 
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However, the increase in NVT cases was similar in these simulations: when ı= 0.5 and ׫ = 377 
0.4, NVT cases increased by 12.1% (95% CI 9.2%ʹ17.8%), and when ı= 0.8 and ׫ = 0.1, 378 
NVT cases increased by 12.7% (95% CI 7.8%ʹ20.1%) by the end of simulation. Dynamics 379 
over time of VT decline differed when ı ZKLFKLVKLJKHUWKDQWKHYDFFLQH¶VVHURW\SH-380 
dependent protection, p = 0.6; before stabilizing, VT disease increased slightly after the initial 381 
decline. 382 
 383 
The estimated median number of deaths averted by PCV13 over twenty years was 384 
proportional to symptomatic infections (Table 2). There were 558 (95% CI 457-656) deaths 385 
averted per 100,000 under-fives over 20 years in the DPT level vaccine coverage scenario in 386 
the base-case, which, extrapolated to the full population, suggests 34,800 (95% CI 29,600±387 
40,800) deaths averted in children under-five per year (the CIs in this case and for other 388 
extrapolations to the entire population do not account for uncertainty of the population size). 389 
We estimated that an additional 13,800 (95% CI 5,600±19,000) deaths would be averted per 390 
year with expanded coverage. However, outcomes for different parameter sets varied 391 
significantly: when immunity parameters were the highest in our range (ı= 0.8 and ׫ = 0.4), 392 
the difference in median deaths averted per year was 11,000 (95% CI 5,400±17,100) in the 393 
DPT level vaccine coverage scenario and 16,200 (95% CI 10,200ʹ21,900) in the extended 394 
vaccine coverage scenario. 395 
 396 
Deaths were inversely related to wealth. In the poorest portion of the population, 178 (95% 397 
CI 127±226) deaths were averted per 100,000 children under-five over the twenty-year 398 
intervention assuming DPT vaccine coverage levels. An additional 55 (95% CI 11±103) 399 
deaths per 100,000 were averted when coverage was increased. The deaths averted in wealth 400 
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quintiles IV and V, the wealthiest forty percent of the population, were significantly lower 401 
than in the poorer population (89 [95% CI 32±122] in quintile IV and 45 [95% CI 19±87] in 402 
quintile V) at DPT coverage levels. Expanded coverage in these groups was not significantly 403 
different from no effect with an estimated -5 [95% CI -37±42] additional deaths averted in 404 
quintile IV and 38 [95% CI -2±60] in quintile V. 405 
 406 
Table 2. Twenty year outcomes and present value costs per 100,000 under-fives by 407 
wealth quintile (all parameter sets) 408 
 I²poorest  II  III  IV  V²richest  Total  
Scenario 1: PCV13 at DPT coverage (76.8%), incremental to the no vaccination scenario  
Deaths 
averted  178 (127±226)  135 (89±184)  116 (66±151)  89 (32±122)  45 (19±87)  558 (457±656)  
OOP 
expenditure 
averted§  
$143 (133±
154)  $109 (102±120)  
$83.7 (71.5±
93.4)  $90.7 (80.4±101)  $111 (97.9±122)  $538 (514±562)  
Money-metric 
VOI§  
$78.0 (70.8±
84.4)  
$36.3 (33.7±
39.7)  
$20.6 (17.6±
23.4)  
$16.2 (14.0±
17.9)  
$8.90 (7.80±
10.0)  $160 (151±168)  
Scenario 2: PCV13 at 90% coverage, incremental to scenario 1  
Deaths 
averted  55 (11±103)  78 (42±115)  16 (-17±58)  -5 (-37±42)  38 (-2±60)  186 (100±272)  
OOP 
expenditure 
averted§  
$51.7 (41.2±
60.7)  
$37.2 (29.5±
44.7)  
$50.5 (42.1±
59.8)  
$32.9 ($24.3±
$43.4)  
$42.2 (33.7±
55.6)  $215 (195±237)  
Money-metric 
VOI§  
$27.9 (22.1±
33.7)  
$12.5 (9.80±
15.3)  
$13.0 (10.7±
14.4)  
$5.90 (4.30±
7.80)  
$3.40 (2.60±
4.70)  $62.6 (55.6±69.6)  
Incremental differences between medians for 20 simulated years in each scenario using base-case parameters: 
intervention scenario 1 incremental to the no vaccination scenario and intervention scenario 2 incremental to scenario 1. 
The totals are for a population of 100,000 under-fives. The distribution of under-fives across wealth quintiles is not equal. 
95% CI in parentheses were constructed by 5,000 bootstrap samples for each scenario overall all parameter sets. 
OOP: Out-of-pocket. 
VOI: value of insurance. 
§
 Present value discounted at 3% annually; US 2014 dollars; in thousands.  
 409 
Financial risk protection 410 
We found that introducing PCV13 into the UIP protected households from the risk of 411 
expenditure on treatment and hospitalization for pneumococcal diseases. The estimated base-412 
case present value out-of-pocket (OOP) expenditure averted per 100,000 was $538,000 (95% 413 
CI $514,000±$562,000) over twenty years at current vaccine coverage levels and an 414 
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additional $215,600 (95% CI $195,000±$237,000) with expanded coverage (Table 2). 415 
Extrapolating to the Indian population, after the fifth year of introducing PCV13 the median 416 
OOP expenditure averted would be approximately $48.7 million annually under DPT vaccine 417 
coverage levels and an additional $13.9 million with expanded coverage.  418 
 419 
The median OOP expenditure averted was estimated to be highest for quintiles I (in the DPT 420 
coverage level scenario, the twenty-year present value was $143,000 [95% CI $133,000±421 
$154,000] per 100,000 under-fives in the base-case), but it showed no clear trend across other 422 
wealth quintiles. The money-metric VOI decreased with wealth. The present value VOI was 423 
$78,000 (95% CI $70,800±$84,400) in wealth quintile I and $8,900 (95% CI $7,800±424 
$10,000) in quintile V per 100,000 children under-five assuming DPT vaccine coverage 425 
levels. Increasing coverage provided additional protection, especially for wealth quintile I. 426 
 427 
Cost and cost-effectiveness 428 
The present value cost of including PCV13 at DPT levels at $3.30 per dose was 429 
approximately $2.8 million per 100,000, and increasing coverage levels to 90% would 430 
increase this cost another $1 million. Extrapolating to the population, the cost is 431 
approximately $240 million each year under DPT coverage levels and $328 million under 432 
expanded coverage. At $1 per PCV13 dose, a similar cost to the rotavirus vaccine, the 433 
respective costs are approximately $112 million and $152 million per year. We estimated the 434 
median YLLs and calculated the cost per YLL averted. The incremental cost per YLL averted 435 
was $144 under DPT vaccine coverage levels in the base-case, and the incremental cost of 436 
expanding coverage was $127. In the sensitivity analysis, the incremental cost per YLL 437 
averted was highest when immunity parameters where highest, reaching $518 per YLL 438 
averted in the DPT vaccination coverage scenario. Figure 3 shows the cost effectiveness 439 
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acceptability curves for all simulations (including all parameter sets). When the willingness 440 
to pay per YLL averted, Ȝ, is greater than $228, we estimate that introducing the vaccine 441 
(scenario 1 + scenario 2) is almost surely (in more than 95% of our simulations) more cost-442 
effective than the baseline scenario. If Ȝ is greater than $325 the extended coverage scenario 443 
is almost surely the most cost-effective option.  444 
 445 
DISCUSSION 446 
India¶VUHFHQWGHFLVLRQWRintegrate the pneumococcal vaccine into its UIP is a response to the 447 
high pneumococcal disease burden in the country [5]. The current cost of PCV is relatively 448 
high and its effectiveness uncertain given the paucity of information on asymptomatic 449 
carriage (the main reservoir of the bacteria), the distribution of IPD-causing serotypes in 450 
India [74], and the potential changes to the serotype distribution after vaccine introduction. 451 
We examined these issues using an ABM. An ABM is helpful in this context as clinical trials 452 
are not feasible for predicting how a mass-vaccination at the population level will affect 453 
serotype distribution. To that end, we simulated the effect of introducing the PCV13 vaccine 454 
into India accounting for differences in population wealth and access to health services.  455 
 456 
We found that the introduction of PCV13 is likely to reduce the disease burden of S. 457 
pneumoniae. The greatest reduction in disease incidence and mortality is predicted to occur in 458 
the first few years after the introduction of the vaccine. This result is similar to other 459 
countries¶ experiences and reflects the significant reduction in the most prevalent serotypes 460 
that are linked to the greatest incidence of disease [75±78]7KRXJKFRORQL]DWLRQOHYHOVGRQ¶W461 
fall as precipitously, the new colonizing serotypes are assumed to have a lower case-carrier 462 
ratio, which results in reductions in disease incidence and mortality. Our estimated percent 463 
decline in disease incidence is modest compared to some studies in HICs [75±78], as well as 464 
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in South Africa [20]. This may be because of our conservative assumption that the vaccine 465 
does not explicitly impact disease incidence, but only affects it implicitly by reducing 466 
carriage of more fit serotypes. However, other factors contribute to the smaller effect on 467 
disease incidence. PCV7 serotypes contributed to a higher percentage of disease incidence in 468 
the pre-vaccine era in HICs (and PCV13 in South Africa [20]) than estimates of PCV13 469 
serotypes contribute to disease in India [38,65]. The impact of vaccination may be even 470 
smaller if the ABM population is not well-mixed²if we assume individuals are more likely 471 
to come into contact with others in their household or region (see supplementary appendix). 472 
Because the vaccination coverage is heterogeneous in the DPT coverage scenario (according 473 
to existing DPT vaccination reported in DLHS-3) there may be unprotected pockets in the 474 
population. These pockets provide a reservoir for PCV13 strains and could propagate 475 
outbreaks of IPD with those strains.   476 
 477 
The cost of implementing the vaccine is not insignificant, we estimated that it would cost at 478 
least $240 million annually, more than double the estimated costs of implementing the 479 
rotavirus vaccine that India recently introduced [30]. If PCV13 cost were to drop from $3.30 480 
per dose to $1, a similar cost to the rotavirus vaccine and likely closer to the cost of a 481 
conjugate vaccine being developed in India, the annual cost would drop to approximately 482 
$112 million. However, including the rotavirus vaccine in the UIP was estimated to reduce 483 
the disease and financial burden more than PCV13. The rotavirus vaccine was estimated to 484 
avert 44,500 deaths assuming DPT coverage [30], while the estimated number of median 485 
deaths averted by PCV13 is approximately 34,800 in our base case. 486 
 487 
The estimate of $144 per YLL in the DPT coverage scenario is a range that would be 488 
considered cost-effective. If willingness to pay per YLL is over $325, introducing the vaccine 489 
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with coverage extended to 90% was the most cost-effective option in over ninety-five percent 490 
of our bootstrap samples. The cost-effectiveness ratios in our analysis are in line with other 491 
projections in low- and middle-income countries studies [24,25,27], but are higher than 492 
studies in Uganda (cost-saving at $0.15 per dose) [26] and in Kenya (mean $47 per disability-493 
adjusted life year at $3.50 per dose) [28]. In addition to assuming different vaccine costs 494 
these studies vary significantly from ours. For example, the study in Uganda does not 495 
consider serotype replacement, and the study in the Kenya assumes replacement will be 496 
similar to the US. In addition, we assumed the vaccine had no impact on the case-carrier 497 
ratio. If we altered that assumption WKHYDFFLQH¶V effectiveness and cost-effectiveness would 498 
be greater. 499 
 500 
Our study has a number of limitations. First and foremost, our estimates are uncertain, which 501 
is a reflection of the uncertainty in the parameters, particularly the efficacy of the vaccine to 502 
reduce the incidence of IPD as well as baseline rates of infection and mortality. Uncertainty is 503 
also partially a function of the size of the simulated population, which was ~25,000, with 504 
children under five representing 3,000±4,000 members of the population. We chose this 505 
population size to focus on a model of serotype dynamics that includes several serotypes. Our 506 
analysis does not fully capture the structural uncertainty of the disease model. We vary 507 
assumptions on the impact of immunity but maintain a similar model structure across 508 
simulations. Additionally, our demographics are based on sampling frameworks of the 509 
population. Though representative, they do not fully capture the heterogeneity that exists in a 510 
population as large as India. Our model does not currently consider sensitivity to the vaccine 511 
dose schedule, and we assume the 2+1 schedule rolled out in India. 512 
 513 
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Although the introduction of the PCV13 vaccine in India is likely to reduce the disease 514 
burden of S. pneumoniae and is cost-effective, the magnitude of the impact is uncertain. Data 515 
collection on pneumococcal carriage, disease, and the prevalent serotypes in India and their 516 
virulence needs to be strengthened. Filling these gaps while also increasing understanding of 517 
pneumococcal dynamics and reducing reliance on assumptions will improve our ability to 518 
project the serotypes likely to emerge and their impact on disease in India after introducing 519 
vaccination. Continuing surveillance after India introduces PCV will inform these dynamics 520 
as well, enhancing effective resource allocation and the success of future initiatives and 521 
course corrections. Though we caution that existing data gaps need to be filled, given our 522 
conservative assumptions, the disease and financial burdens averted and the relatively low 523 
expected cost per YLL saved makes this an intervention worth pursuing.    524 
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 FIGURE LEGENDS 794 
Figure 1. Pneumococcal Disease Cases (base-case) 795 
Median pneumococcal disease incidence by year for 5,000 bootstrap samples using base-case 796 
parameters. The line representing the no vaccination scenario is the median across all years. The 797 
shaded areas represent the 95% CI for each year. The vertical lines with arrows and the 798 
corresponding values are the median cases averted after year 5, and the values in parentheses are 799 
the 95% CIs. 800 
 801 
Figure 2. Sensitivity to immunity parameters 802 
Sensitivity of pneumococcal disease cases, including non-severe and severe pneumococcal 803 
pneumonia, pneumococcal meningitis, and other invasive pneumococcal infections, to immunity 804 
parameters over 5,000 bootstrap samples. Panel (A) shows estimated cases averted per year for each 805 
parameter set. It is calculated by subtracting the median cases in scenario 1 and median cases in 806 
scenario 2 from the median cases in the no vaccination scenario for each bootstrap sample. Dots and 807 
triangles are the predictions and line ranges are the 95% CIs. The other panels show serotype 808 
replacement over time; plotted values are the medians for each year. Panel (B) shows the percent 809 
reduction in vaccine type cases of pneumococcal disease and (C) the percent increase in non-vaccine 810 
type pneumococcal cases after the introduction of PCV13 to 90% of the population (scenario 2). 811 
઩: Serotype-independent immunity shape parameter (see equation 4). 812 
ʍ ?ŶƚŝĐĂƉƐƵůĂƌ ?ƐĞƌŽƚǇƉĞ-specific) immunity parameter (see equation 1). 813 
  814 
Figure 3. Cost-effectiveness acceptability curves 815 
Cost-effectiveness from health system perspective. Includes all simulations. 816 
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S1 Appendix 
- IndiaSim agent-based simulation model structure 
IndiaSim is an agent-based model (ABM) programmed in C++11 standard. The ABM was previously 
used to analyse the introduction of rotavirus vaccination in the UIP [1], expanding neonatal care by 
community health workers [2], universal public finance of epilepsy treatment [3], and implement 
water and sanitation interventions to reduce diarrheal diseases [4] among other analyses. The model 
is representative of the Indian population at the district level. It was constructed using the District 
Level Household Survey 2007 W2008 (DLHS-3), which includes data on 34 Indian states (Nagaland is 
excluded), approximately 720,000 Indian households, and 3.4 million individuals. The survey 
reported information on individual characteristics (e.g., age, and sex) and household socioeconomic 
status. The survey also includes information health care facilities (e.g., their location and quality) and 
ŽŶŚŽƵƐĞŚŽůĚƐ ?ĐĂƌĞ-seeking behaviour. 
 
The ABM is structured in 67 patches, describing geographical units. Each patch is the urban or rural 
ƌĞŐŝŽŶŝŶĂƐƚĂƚĞ ?ŶĚĂŵĂŶĂŶĚEŝĐŽďĂƌ ?ƐƵƌďĂŶƌĞŐŝŽŶŝƐĞǆĐůƵĚĞĚďĞĐĂƵƐĞŽĨƐŵĂůůƐĂŵƉůĞƐŝǌĞ ? ?
Each patch is populated by individuals, grouped into household units (for this analysis approximately 
4,300 households were drawn from DLHS-3). Decisions in the model, including healthcare seeking 
and vaccination ones, are made at the household level. Households decide whether to vaccinate to 
protect from disease, and they decide whether to seek care when household members exhibit 
disease symptoms. For more details on the ABM see previous publications [1 W3].  
 
- Disease model 
We modelled the dynamics of pneumococcal disease by building on a colonization model by Cobey 
and Lipsitch 2012 [5]. The model used similar assumptions, but was modified to include infection. At 
each time-step, a host carrying serotype ݖ transmits to ݔ individuals, where ݔ is drawn from a 
Poisson distribution with a mean ߚܫ௭. ߚ ŝƐƚŚĞĞĨĨĞĐƚŝǀĞĐŽŶƚĂĐƚƌĂƚĞ ?ĂƉƌŽĚƵĐƚŽĨƚŚĞŚŽƐƚ ?ƐĐŽŶƚĂĐƚƐ
and likelihood of transmission, and  ܫ௭ is the number of strains of serotype ݖ the host carries. The ݔ 
individuals the host transmits to are randomly picked from the entire population, where for each 
individual in the population the probability of being picked is weighted by their location relative to 
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the host and the parameter for fraction of contacts from within the same household (ߩ௛), within the 
same patch (ߩ௣), and neither ሺ⁡? െ ߩ௛ െ ߩ௣ሻ. 
 
Each of the ݔ individuals acquires the strain based on their susceptibility. Similarly to Cobey and 
Lipsitch 2012 [5], host susceptibility to pneumococcal colonization by strain ݖ is given by: 
 ݍ൫ݖǡ ߠԦǡ ܥԦ൯ ൌ ൣ⁡? െ ൫߱ܥԦ൯൧ ቂ⁡? െ݉ ݅݊ ቀሺ⁡? െ ݌ሻǡ൫⁡?ǡ ߪ ⁡? ߬ሺݖሻ൯ቁቃ (1)  
where ߠԦ and  ܥԦ are vectors of past and current colonization indexed by ݖ. The term in the second 
bracket of (1) represents naturally acquired and vaccine serotype-specific immunity. ݌  is vaccine 
efficacy for the targeted serotypes. ߪ is an anticapsular immunity parameter (equivalent for all 
serotypes) and   
 ߬ሺݖሻ ൌ ൜⁡?ǡ ߠ௭ ൌ ⁡?ሺሻ⁡?ǡ ߠ௭ ൐ ⁡?ሺሻǤ  
 
(2)  
Host susceptibility is also a function of the serotypes currently carrying (the strain competition) 
represented by the term in the first bracket in (1). Competition is represented by 
 ߱൫ܥԦ൯ ൌ ۖەۖ۔
ۓ ⁡?ǡ ෍ܥ௜ ൌ ⁡?ሺሻߤ௠௔௫ ൥⁡? െ݉ ݅݊൫ Ԧ݂൯ െ ⁡?ܼ െ ⁡? ൩ ǡ  ෍ܥ௜ ൐ ⁡?ሺሻǤ  (3)  
where ܼ is the number of serotypes in the model,  ߤ௠௔௫ is the maximum scaling down of 
susceptibility due to strain competition, and Ԧ݂ is a vector of serotype fitness ranks such that ݉݅݊൫ Ԧ݂൯ 
is the rank of the most fit carried serotype. 
 
The duration of a new colonization in a host is drawn from an exponential distribution with a mean 
 ݒሺݖሻ ൌ ݇ ൅ ሾߛሺݖሻ െ ݇ሿ݁ିఢ ⁡? ఏ೔೔  (4)  
where ݇ is the minimum duration of colonization, ߛሺݖሻ is a serotype specific intrinsic colonization 
duration, and ߳ is a fitted shape parameter (see in [5] for fit). Duration exponentially decreases with 
the sum of past colonization, describing the non-specific immunity. 
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Carriers of strain ݖ can become infected with the daily likelihood ߟሺݖሻ, which was equivalent across 
serotypes in our simulations, and infected individuals die according to the case-fatality rate. 
 
- Simulation and fitting 
Our estimates are based on a 20 year simulation time frame (in discrete time-steps of one week) for 
the three scenarios: the baseline scenario without PCV; scenario 1 with PCV13 coverage at 
households that also get DPT vaccination (approximately 77%); and scenario 2 with 90% PCV13 
coverage. Each scenario was simulated using 6 different parameter sets: under-five colonization 
prevalence was set to 40%; the serotype specific immunity parameter, ʍ, was set to 0.5 or 0.8; and 
the non-specific immunity parameter, ઩, was set to 0.1, 0.25, or 0.4; vaccination and treatment costs 
in public and private providers were also varied. These parameters are described further in the 
disease model section and the choice of their values is described in Table 1.  
 
To initialize our populationƐ ? carriage and immunity distributions, we ran each parameter set for a 
200 year burn-in period with no vaccination. We fit the simulations to three indicators: under-five 
colonization prevalence, the observed number of pneumococcal infections, and the number of 
deaths. Two sources estimated pneumococcal pneumonia, pneumococcal meningitis, and other 
invasive pneumococcal disease cases and mortality in India in the early 2000s [6,7], and two other 
studies have estimated these values for pneumococcal pneumonia in 2010 [8,9]. To achieve the fit, 
we did a parameter sweep, altering the contact rate (ɴ), the daily rate of infection (for carriers), and 
the case fatality rate; we drew 100 samples for each of the 6 parameter sets using Latin Hypercube 
Sampling (LHS). We simulated each of the samples 10 times for a total of 6,000 simulations.  
 
The best fits from the simulations used to initialize our populations were used as the starting point 
for simulations we used in the analysis. For this analysis, all three scenarios were simulated 100 
times from each of the starting points using their respective values for ʍ, ઩, and the fitted 
parameters. We then ran a total of 1,800 simulations (3 scenarios, 6 parameter sets, and 100 runs of 
each).  
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-4 Estimating outcomes 
We estimated outcome measures and 95% CIs by drawing 5,000 bootstrap samples. 
Incremental government expenditure and private, out- -pocket expenditure averted 
We considered cost of care-seeking, diagnostics, and treatment, including hospitalization and 
medication. These costs are out of pocket in all scenarios. Government expenditure is for 
ŝŶƚƌŽĚƵĐŝŶŐĂŶĚŝŶĐůƵĚŝŶŐƚŚĞƉŶĞƵŵŽĐŽĐĐĂůĐŽŶũƵŐĂƚĞǀĂĐĐŝŶĞŝŶ/ŶĚŝĂ ?ƐhŶŝǀĞƌƐĂů/ŵŵunization 
Programme (UIP). dŚĞƐĞĐŽƐƚƐĂƌĞĨƌŽŵ/ŶĚŝĂ ?Ɛ comprehensive multi-year plan (cMYP) for 
immunization [10] as described in the manuscript.  
 
Using the outputs from IndiaSim we calculated the present day incremental values for both 
government costs and out-of-pocket (OOP) expenditure averted for each scenario. All costs were 
converted to 2014 US dollars using the Internal Revenue Service yearly average currency exchange 
rates [11] and GDP deflators [12]. 
 
Years of life lost (YLLs) and cost per YLL 
We calculated the years of life lost YLLs averted using IndiaSim outputs on deaths due to 
pneumococcal infections. We also calculated the dollars-per-YLL averted. Costs included OOP 
expenditure and costs to the government for including the vaccine in the UIP. We discounted at 3% 
assuming uniform age-weights.  
 
Money-metric value of insurance 
We estimated the financial risk protection of averting out-of-pocket expenditure on care and 
treatment for individuals with pneumococcal infections. To estimate this we calculated the money-
metric value of insurance, using a constant relative risk aversion utility function. For more 
information on this calculation please see Verguet et al. 2015 [13] and the appendix in Megiddo et 
al. 2016 [3]. 
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